Skip to main content
. 2013 Oct 24;1(5):e00133. doi: 10.1002/phy2.133

Table 1.

Summary of LTD-LTP studies.

Condition (N) LFS (%) HFS (%)
Control (6) 65.9 ± 5.9 67.3 ± 5.7
50 μmol/L D-APV during LFS (6) 107.5 ± 3.2 143.9 ± 9.2
5 μmol/L D-APV during LFS (5) 79.9 ± 4.5 102.1 ± 24.8
5 μmol/L D-APV continuously (5) 73.8 ± 2.9 92.3 ± 5.3
1 μmol/L PTX continuously (5) 102.4 ± 2.8 166.4 ± 18.9
1 μmol/L Finasteride continuously (5) 104.1 ± 12.0 134.2 ± 14.2
1 μmol/L Finasteride during LFS (5) 97.8 ± 2.9 91.6 ± 7.3
1 μmol/L Finasteride after LFS (5) 56.6 ± 4.8 101.5 ± 13.4